MedTrace Logo

DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays

NCT07693894 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2080

Last updated 2026-07-09

No results posted yet for this study

Summary

Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.

Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care.

The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer.

The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer.

This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.

Conditions

Interventions

DIAGNOSTIC_TEST

Investigational ovarian cancer biomarker assays

Collection of blood samples for investigational ovarian cancer biomarker analyses (OVA-GLY, OVA-VOC and OVA-miRNA).

Sponsors & Collaborators

  • European Commission

    collaborator OTHER

  • National and Kapodistrian University of Athens

    lead OTHER

Eligibility

Min Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-12-31
Completion
2028-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07693894 on ClinicalTrials.gov